Lilly's rival to Novo's new Awiqli insulin gets FDA approval
The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik, setting up a market tussle with Novo's recently launched Awiqli.
Newsletters and Deep Dive digital magazine
The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik, setting up a market tussle with Novo's recently launched Awiqli.
While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.
FDA expert advisors voted in favour of Grail's Galleri blood test for detecting multiple cancers, but some expressed misgivings about its efficacy.
Europe's top pharma firms have called on governments to take action to change the region's story from one of decay to one of "renewal and resilience."
CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.
Editor's Picks
Newsletters and Deep Dive
digital magazine